drugset / Trial / NCT01222351

Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

NCT01222351

NaSingle-groupOpen-labelDiagnostic

Summary

The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline. The investigators will use baseline and longitudinal measurements of plasma amyloid beta-40 and amyloid beta-42 to investigate the risk of developing mild cognitive impairment and late onset Alzheimer's disease, as well as the rates of cognitive decline and Alzheimer's disease progression. The driving hypothesis of the study is that amyloid beta in the brain as measured by positron emission tomography positivity is associated with the onset of cognitive decline associated with late onset Alzheimer's disease.

Timeline

Start
2010-12
Primary completion
2014-10-22
Completion
2014-10-22

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-Florbetaben Diagnostic / imaging agent

Indications